| abstract |
The invention relates to the field of biomedicine, in particular to a series of derivatives of a novel CDK9 inhibitor with a benzofuran structure and application thereof; aiming at the defects of low antitumor activity and poor druggability of wogonin, the invention modifies the mother nucleus to synthesize a series of compounds, particularly introduces N-containing cyclic substituent groups to 3 'or 4' positions, the compounds are brand new compounds and are not reported in documents, and meanwhile, the inventor carries out a series of biological activity evaluation on the synthesized compounds, specifically, most of the compounds have good selectivity on CDK9 and have good inhibitory activity on cancer cells. |